You are viewing: Rest Of Europe Compounding Pharmacy Market analysis
Part of: Compounding Pharmacy Market (Global)

The Rest Of Europe Compounding Pharmacy Market was valued at $230.8 Million in 2025 and projected to reach to $288.5 Million by 2030, representing a compound annual growth rate of 4.6%. The Rest Of Europe compounding pharmacy market is positioned for steady growth through 2030, supported by rising healthcare expenditures and increasing patient awareness of personalized medicine benefits.

Rest Of Europe Compounding Pharmacy Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Rest Of Europe Compounding Pharmacy Market Trends and Insights

  • Rest Of Europe represents a significant segment within the broader European compounding pharmacy landscape, driven by increasing demand for personalized medication solutions and regulatory support for pharmaceutical compounding.
  • The market in Rest Of Europe is characterized by a growing emphasis on patient-centric care, rising prevalence of chronic diseases, and expanding healthcare infrastructure across multiple countries in the region. Rest Of Europe's compounding pharmacy sector benefits from favorable reimbursement policies and heightened awareness among healthcare providers regarding the benefits of customized pharmaceutical preparations.
  • Between 2025 and 2030, Rest Of Europe is expected to experience steady market expansion as pharmacies invest in advanced compounding technologies and skilled personnel.
  • The region's market growth is supported by an aging population, increased adoption of specialty compounding services, and strengthening regulatory frameworks that ensure quality and safety standards in compounding operations..

Key Market Statistics

  • CAGR (2025-2030) 4.6% CAGR
  • Market Size, 2025 ~USD 230.8 Million
  • Forecast, 2030 ~USD 288.5 Million
  • Country Rest Of Europe

Rest Of Europe Compounding Pharmacy Market Overview

Market Valuation :

Rest Of Europe compounding pharmacy market valued at USD 230.8 million in 2025, demonstrating substantial market presence across non-major European economies.

Growth Trajectory :

Market projected to reach USD 288.5 million by 2030 with a CAGR of 4.6%, indicating steady expansion driven by personalized medication demand.

Regulatory Environment :

Rest Of Europe benefits from supportive regulatory frameworks that encourage compounding pharmacy practices, facilitating market growth and operational expansion.

Personalization Trend :

Increasing adoption of customized medication solutions across Rest Of Europe reflects growing patient preference for tailored pharmaceutical treatments over standard formulations.

Rest Of Europe Compounding Pharmacy Market Dynamics

  • The region's diverse healthcare systems create opportunities for compounding pharmacies to address unmet medication needs and provide customized solutions for chronic disease management. Key growth drivers include aging populations, expanding chronic disease prevalence, and regulatory support for compounding practices across Rest Of Europe.
  • Market players are expected to invest in advanced compounding technologies and quality assurance measures to meet evolving patient demands and maintain competitive positioning in this moderately growing segment..

Market Ecosystem

logo-mobile

COMPOUNDING PHARMACY MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Provides sterile and non-sterile compounding services, including ready-to-dispense and ready-to-administer personalized medicines for pharmacies, hospitals, and clinics | Its compounding operations support customized strengths, dosage forms, ingredient requirements, and therapies where commercially available medicines may be unsuitable or unavailable. Enables healthcare providers to address patient-specific medication requirements, drug shortages, discontinued products, allergies, and dosage-form limitations while outsourcing complex sterile and non-sterile compounding activities.
company logo
Operates both a 503A compounding pharmacy for patient-specific prescriptions and an FDA-registered 503B outsourcing facility for office-use medications | Its portfolio includes compounded preparations across multiple therapeutic areas and dosage forms, supported by sterile batch testing and cGMP processes at the 503B facility. Expands access to individualized medicines and multiple strengths and dosage forms while enabling healthcare providers to procure larger-scale compounded products from a regulated outsourcing facility.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • Pfizer Inc.
  • NOVARTIS

    Key Takeaways

    • Rest Of Europe's compounding pharmacy market is valued at USD 230.8 million in 2025 and will reach USD 288.5 million by 2030.
    • Rest Of Europe is experiencing a 4.6% CAGR, reflecting steady growth driven by personalized medication demand and regulatory support.
    • Rest Of Europe's market expansion is fueled by an aging population, chronic disease prevalence, and investment in advanced compounding technologies.
    • Rest Of Europe benefits from favorable reimbursement policies and strengthening regulatory frameworks that enhance market confidence and service quality.

    Compounding Pharmacy Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment HORMONE REPLACEMENT THERAPIES (Therapeutic Application)
    Forecast Period 2025–2030
    Growth Rate CAGR of 5.7% from 2025 to 2030
    Largest Segment PHARMACEUTICAL DOSAGE ALTERATION (Compounding Type)
    Market Size Base Year (Billions) ~USD 14.71 (2025)
    Revenue Forecast (Billions) ~USD 19.41 (2030)
    Segments Covered Product, Compounding Type, Therapeutic Application

    Rest Of Europe Compounding Pharmacy Market Report Segmentation

    3 segment dimensions are covered across the global market.

    By Product

    • Nasal Drugs
    • Ophthalmic Drugs
    • Oral Drugs
    • Other Products
    • Parenteral Drugs
    • Rectal Drugs
    • Topical Drugs

    By Compounding Type

    • Currently Unavailable Pharmaceutical Manufacturing
    • Pharmaceutical Dosage Alteration
    • Pharmaceutical Ingredient Alteration

    By Therapeutic Application

    • Dermal Disorders
    • Hormone Replacement Therapies
    • Nutritional Supplements
    • Other Therapeutic Applications
    • Pain Management

    Target Audience

    • Pharmaceutical Manufacturers : Need Rest Of Europe market data to identify compounding opportunities, assess regional demand for customized formulations, and develop localized product strategies.
    • Compounding Pharmacy Operators : Require market sizing and growth forecasts to evaluate expansion potential, benchmark performance, and make informed decisions about facility investments in Rest Of Europe.
    • Healthcare Investors : Seek regional market analysis to evaluate investment opportunities in compounding pharmacy businesses, assess risk-return profiles, and identify high-growth markets within Rest Of Europe.
    • Healthcare Consultants : Need Rest Of Europe-specific data to advise clients on market entry strategies, competitive positioning, and growth opportunities in the compounding pharmacy sector.
    • Regulatory & Policy Bodies : Require market intelligence on Rest Of Europe compounding pharmacy trends to inform policy development, regulatory frameworks, and healthcare system planning initiatives.

    Key Companies in the Rest Of Europe Compounding Pharmacy Market

    CompanyHQOwnershipStrongest segments
    BAXTERUnited StatesPublic CompanyMedical Products & Therapies (IV, infusion, parenteral nutrition, renal-related therapies),Healthcare Systems & Technologies (smart beds, monitoring, OR integration, surgical equipment),Pharmaceuticals (generic and specialty injectables, inhaled anesthetics, compounding services),
    FAGRONBelgiumPublic CompanyEssentials (APIs, excipients, bases),Brands (derma, immunology, hair, scar care),Compounding Services,

    BAXTER

    Baxter is a publicly traded American healthcare company founded in 1931 that employs 37,500 people. The company operates as a major medical device and pharmaceutical manufacturer serving global markets.

    FAGRON

    Fagron is a publicly traded Belgian pharmaceutical company founded in 1990 with 4,880 employees. The company focuses on pharmaceutical compounding and specialty pharmacy solutions.

    Reasons to Buy this Report

    • Regional Market Sizing : Obtain precise valuation data for Rest Of Europe compounding pharmacy market with verified 2025 baseline (USD 230.8M) and 2030 projections, enabling accurate business planning and investment decisions.
    • Growth Forecasting : Access detailed CAGR analysis (4.6%) specific to Rest Of Europe, allowing stakeholders to benchmark performance against regional trends and identify expansion opportunities.
    • Competitive Intelligence : Understand Rest Of Europe market dynamics, regulatory drivers, and personalization trends to develop targeted strategies for market entry or expansion in this emerging segment.
    • Investment Validation : Leverage comprehensive market data to validate investment theses, secure funding, and justify resource allocation for compounding pharmacy ventures across Rest Of Europe.
    • Strategic Planning : Utilize Rest Of Europe-specific insights to inform product development, partnership strategies, and market positioning aligned with regional healthcare demands and regulatory requirements.

    Frequently asked questions

    What is the market size of compounding pharmacies in Rest Of Europe in 2025?

    The compounding pharmacy market in Rest Of Europe is valued at USD 230.8 million in 2025.

    What is the projected market size for Rest Of Europe's compounding pharmacy market by 2030?

    Rest Of Europe's compounding pharmacy market is projected to reach USD 288.5 million by 2030.

    What is the CAGR for the compounding pharmacy market in Rest Of Europe?

    Rest Of Europe's compounding pharmacy market is growing at a CAGR of 4.6% from 2025 to 2030.

    What factors are driving growth in Rest Of Europe's compounding pharmacy market?

    Growth in Rest Of Europe is driven by increasing demand for personalized medications, an aging population, rising chronic disease prevalence, and strengthening regulatory frameworks.

    How does Rest Of Europe's compounding pharmacy market compare to global trends?

    Rest Of Europe's 4.6% CAGR is slightly lower than the global CAGR of 5.7%, indicating a more moderate but stable growth trajectory in the region.

    RESEARCH METHODOLOGY

    This study involved four major activities to estimate the current size of the compounding pharmacy market. We conducted exhaustive secondary research to gather information on the market, its peer markets, and its parent market. The team then validated these findings, assumptions, and sizing with industry experts across the value chain through primary research. We used both top-down and bottom-up approaches to estimate total market size. We then used data triangulation to estimate market size by segment and subsegment.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the compounding pharmacy market. The secondary sources used for this study include US Food and Drug Administration (FDA), American Pharmacists Association (APhA), International Academy of Compounding Pharmacists (IACP), National Community Pharmacists Association (NCPA), Parenteral Drug Association (PDA), American Society of Health-System Pharmacists (ASHP), Pharmacy Compounding Accreditation Board (PCAB), European Directorate for the Quality of Medicines & HealthCare (EDQM), European Medicines Agency (EMA), International Pharmaceutical Federation (FIP), Journal of Compounding & Specialty Pharmacy (JCSP), National Center for Biotechnology Information (NCBI), Pharmaceutical Research and Manufacturers of America (PhRMA), Pharma & Biopharma Outsourcing Association (PBOA), and World Journal of Pharmaceutical Research (WJPR). Secondary sources also include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; trade, business, and professional associations; and MarketsandMarkets Analysis. These sources were also used to obtain key information on major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    We conducted in-depth interviews with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. We interviewed primary sources from both the supply and demand sides of the market to gather qualitative and quantitative data. The following is a breakdown of the primary respondents:

    Compounding Pharmacy Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    We estimated the global size of the compounding pharmacy market using multiple approaches. We used a detailed market estimation approach to estimate and validate the market value and other dependent submarkets. We also used these methods extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following.

    Compounding Pharmacy Market: Top-Down and Bottom-Up Approach

    Compounding Pharmacy Market Top Down and Bottom Up Approach

    Data Triangulation

    After estimating the market size using the process described above, we divided the total market into several segments and subsegments. To complete the overall market analysis and obtain precise statistics for all segments and subsegments, we used data triangulation and market breakdown methods where applicable. We triangulated the data by examining factors and trends from both the demand and supply sides.

    Market Definition

    A compounding pharmacy is a specialized practice in which a licensed pharmacist combines, mixes, or alters raw drug ingredients to formulate customized medications tailored to individual patients' unique health needs. This process allows pharmacists to create pharmaceutical products in various forms, such as liquids, creams, gels, or capsules, and can be vital for patients with specific allergies, intolerances, or those needing dosages not commercially available. Compounding pharmacists often work closely with healthcare providers to develop formulas that address particular medical conditions, ensuring that each preparation is safe, effective, and personalized to optimize patient care. Additionally, compounding pharmacies adhere to stringent regulatory standards to maintain the integrity and quality of the medications they produce.

    Key Stakeholders

    • Pharmaceutical & Biotechnology Companies
    • Compounding Pharmacies
    • Research & Consulting Firms
    • Academic Medical Centers
    • Government Regulatory & Research Organizations
    • Quality Assurance & Accreditation Bodies
    • Clinical Research Institutes

    Report Objectives

    • To define, describe, and forecast the compounding pharmacy market based on product, compounding type, therapeutic application, sterility, end user, and region
    • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall compounding pharmacy market
    • To analyze opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to five regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), and the Middle East & Africa (GCC Countries and the Rest of Middle East & Africa)
    • To profile the key players and analyze their market share and core competencies
    • To analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

    Available customizations:

    With the given market data, MarketsandMarkets offers customization as per the company’s specific needs. The following options are available for the report:

    Geographical Analysis

    • A further breakdown of the Rest of Asia Pacific compounding pharmacy market into countries
    • A further breakdown of the Rest of Europe compounding pharmacy market into countries
    • A further breakdown of the Rest of Latin America compounding pharmacy market into countries

    Company Information

    • Detailed analysis and profiling of additional market players (up to five).
     

     

    Get the Full Compounding Pharmacy Market Report

    Full forecast, segment splits, and company analysis for all Compounding Pharmacy Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status